Privacy in Biomarker Doctrine Accountability

Introduction

Privacy in biomarker doctrine accountability refers to the legal principles and institutional responsibilities governing the collection, analysis, storage, disclosure, and commercial use of biomarker information. Biomarkers are measurable biological indicators, including hormones, proteins, blood glucose levels, genetic variations, and disease-related substances. They are increasingly used in medical diagnosis, personalised medicine, pharmaceutical research, and predictive healthcare.

Biomarker information can reveal sensitive facts about an individual's present health, future disease risks, and biological characteristics. Accountability doctrine therefore requires hospitals, laboratories, researchers, pharmaceutical companies, and regulators to protect confidentiality and prevent unauthorised or discriminatory use of biological information.

Legal Framework in India

Article 21 of the Indian Constitution protects privacy as a fundamental right, while Article 14 provides protection against arbitrary state action. The Digital Personal Data Protection Act, 2023, may apply when biomarker information constitutes digital personal data within its scope, subject to applicable commencement provisions, rules, and exemptions. The Information Technology Act, 2000, and relevant rules may also apply in appropriate circumstances.

Accountability requires lawful data processing, appropriate consent where legally required, purpose limitation, reasonable security measures, and effective remedies for violations. It also requires distinguishing genuinely anonymised research data from information that can be linked to an identifiable individual.

Important Case Laws

1. Justice K.S. Puttaswamy (Retd.) v. Union of India (2017)

The Supreme Court of India unanimously recognised privacy as a fundamental right under the Constitution. The judgment established that restrictions on privacy must satisfy the requirements of legality, legitimate state purpose, and proportionality.

This case provides the principal constitutional foundation for biomarker privacy. Government agencies and other regulated institutions must respect applicable privacy protections when collecting or using sensitive biological information.

Indian Kanoon+1

2. K.S. Puttaswamy v. Union of India (Aadhaar judgment, 2018)

The Supreme Court examined the constitutional validity of Aadhaar's biometric identification framework. Its analysis addressed the collection, use, disclosure, and security of biometric information, including restrictions on certain forms of private-sector use.

The decision is relevant to biomarker governance because it demonstrates the importance of limiting sensitive information to legally authorised purposes. However, Aadhaar biometrics and medical biomarkers are distinct categories, and the judgment does not establish a comprehensive biomarker-specific legal regime.

Indian Kanoon+1

3. Mr. X v. Hospital Z (1998)

The Supreme Court considered the disclosure of a patient's HIV-positive status to his prospective spouse. It recognised medical confidentiality and privacy but held, in the circumstances of that case, that disclosure was justified to protect the prospective spouse's health.

The case illustrates that confidentiality may have limited exceptions where competing rights or serious health concerns arise. For biomarker accountability, it supports careful evaluation of whether disclosure is legally justified, necessary, and proportionate rather than treating all biological information as freely shareable.

Global Health & Human Rights Database+1

Major Challenges in Biomarker Accountability

Informed consent: Individuals should understand the purpose and foreseeable uses of biomarker testing.

Secondary use: Research or commercial reuse should comply with applicable law and consent requirements.

Data security: Laboratories and healthcare providers must protect records against unauthorised access and disclosure.

Genetic and health discrimination: Biological findings may be misused in employment, insurance, or other decisions.

Re-identification: Combining supposedly anonymous biological datasets with other information may expose identities.

Institutional responsibility: Organisations need clear accountability procedures, audit mechanisms, and effective complaint and redress systems.

Conclusion

Privacy in biomarker doctrine accountability combines constitutional rights, data-protection obligations, medical confidentiality, and institutional responsibility. Puttaswamy establishes the constitutional foundation for privacy, the Aadhaar judgment provides relevant principles for governing biometric information, and Mr. X v. Hospital Z illustrates the balance between confidentiality and justified disclosure.

An effective biomarker governance framework should ensure lawful collection, appropriate consent, restricted disclosure, secure storage, transparent institutional responsibility, and proportionate remedies. These safeguards can support scientific and medical progress while protecting individual dignity, autonomy, and informational privacy.